On January 4, 2020 Johnson & Johnson (NYSE: JNJ) reported that its Board of Directors has declared a cash dividend for the first quarter of 2021 of $1.01 per share on the company’s common stock (Press release, Johnson & Johnson, JAN 4, 2021, View Source;johnson-announces-quarterly-dividend-for-first-quarter-2021-301200054.html [SID1234573446]). The dividend is payable on March 9, 2021 to shareholders of record at the close of business on February 23, 2021. The ex-dividend date is February 22, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 4, 2021 Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, reported that the company will participate in the upcoming 39th Annual J.P. Morgan Healthcare Conference (Press release, Ascendis Pharma, JAN 4, 2021, View Source [SID1234573395]). Company executives will provide a business overview and update on the company’s pipeline programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details

Event 39th Annual J.P. Morgan Healthcare Conference
Location Virtual
Date Monday, January 11, 2021
Time 11:40 a.m. Eastern Time
A live webcast of the presentation will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the events for 30 days.

On January 4, 2021 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, reported that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright Bioconnect 2021 Conference which will be available on demand starting on January 11, 2021 at 6:00 am (ET) (Press release, Mannkind, JAN 4, 2021, View Source [SID1234573412]). Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at View Source The webcast replay will remain available for 14 days following the live presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 4, 2021 Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, reported that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021, at 11:30 a.m. Eastern time (Press release, Castle Biosciences, JAN 4, 2021, View Source [SID1234573429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at View Source A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

On January 4, 2021 Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, reported that Eric Ostertag, M.D., Ph.D., Poseida Therapeutics’ Chief Executive Officer, will participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event taking place from January 11-14, 2021 (Press release, Poseida Therapeutics, JAN 4, 2021, View Source [SID1234573447]). In addition, management will be available for one-on-one meetings with investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for on-demand viewing on the Investors & Media Section of the Poseida website, www.poseida.com, beginning Monday, January 11, 2021 at 7:00 a.m. ET and will be available for approximately 30 days.